HDL-C Response Variability to Niacin ER in US Adults
Table 3
Predictors of response to niacin ER (500 mg dose).
High responder1 ()
Low responder2 ()
Crude OR (95% CI)3
Adjusted OR (95% CI)3,4
(%)
(%)
Age (years, continuous)
—
—
0.10 (0.97–1.02)
1.0 (0.97–1.03)
Gender
Female
39 (32.5%)
53 (29.1%)
1.0
1.0
Male
81 (67.5%)
129 (70.9%)
0.85 (0.52–1.40)
0.79 (0.25–2.51)
HDL-C mg/dL (males only)
≥40
49 (40.8%)
111 (61.0%)
1.0
1.0
40
71 (59.2%)
71 (39.0%)
2.27 (1.42–3.63)
5.18 (2.36–11.39)
HDL-C mg/dL (females only)
≥50
87 (72.5%)
155 (85.2%)
1.0
1.0
<50
33 (27.5%)
27 (14.8%)
2.18 (1.23–3.86)
5.40 (1.84–15.79)
LDL-C mg/dL
<130
69 (57.5%)
103 (56.6%)
1.0
1.0
≥130
51 (42.5%)
79 (43.4%)
0.96 (0.61–1.54)
1.23 (0.54–2.77)
TG mg/dL
<150
32 (26.7%)
71 (39.0%)
1.0
1.0
≥150
88 (73.3%)
111 (61.0%)
1.76 (1.06–2.91)
1.38 (0.76–2.50)
TC mg/dL
<200
62 (51.7%)
85 (46.7%)
1.0
1.0
≥200
58 (48.3%)
97 (53.3%)
0.82 (0.52–1.30)
1.0 (0.42–2.34)
Diabetes
No
82 (68.3%)
138 (75.8%)
1.0
1.0
Yes
38 (31.7%)
44 (24.2%)
1.45 (0.87–2.43)
1.41 (0.78–2.52)
Stroke (within 6 months)
No
114 (95.0%)
174 (95.6%)
1.0
1.0
Yes
6 (5.0%)
8 (4.4%)
1.15 (0.39–3.39)
0.69 (0.19–2.49)
Hypertension (within 6 months)
No
108 (90.0%)
171 (94.0%)
1.0
1.0
Yes
12 (10.0%)
11 (6.0%)
1.73 (0.74–4.05)
1.91 (0.71–5.15)
Ischemic heart disease (within 6 months)
No
97 (80.8%)
147 (80.8%)
1.0
1.0
Yes
23 (19.2%)
35 (19.2%)
1.0 (0.56–1.79)
0.91 (0.44–1.87)
Statin use during baseline
No
50 (41.7%)
63 (34.6%)
1.0
1.0
Yes
70 (58.3%)
119 (65.4%)
0.74 (0.46–1.19)
0.69 (0.37–1.31)
Fibric acid use during Baseline
No
10 (8.3%)
22 (12.1%)
1.0
1.0
Yes
110 (91.7%)
160 (87.9%)
1.51 (0.69–3.32)
1.60 (0.69–3.75)
Definition of lipids: HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; TC: total cholesterol.
1High responder: HDL-C effect > 15%.
2Low responder: HDL-C effect < 5%.
3Outcome is high responder.
4Adjusted model includes all variables listed in the table.
